The company offers prescription pharmaceuticals in six therapeutic areas: cardiovascular, thrombosis, metabolic disorders, oncology, central nervous system, and internal medicine.
Its product portfolio includes Aprovel and Tritace, two hypertension treatment products for cardiovascular diseases; metabolic disorders products, which includes Lantus, a long acting analogue insulin and Amaryl, a once-daily sulfonylurea; oncology drugs that include Taxotere, a taxane derivative representing a cornerstone therapy in various cancer types, and Eloxatine, an platinum agent for metastatic colorectal cancer; central nervous system medicines, which include Stilnox for insomnia, Copaxone for multiple sclerosis, and Depakine for epilepsy treatments; and internal medicine products that include Allegra for respiratory/allergy, Nasacort for allergic rhinitis, Xatral for prostatic hypertrophy, and Actonel for osteoporosis.
The company also offers various human vaccines, which include pediatric combination vaccines, influenza vaccines, polio vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel vaccines.
As of December 31, 2004, Sanofi-Aventis had a total of 128 compounds in development in seven therapeutic areas, including 20 for vaccines, 48 of which were in phase II or phase III clinical trials.
In addition, the company manufactures and markets various over the counter and generic products.
It offers its products approximately in 100 countries.
The company has alliances with Bristol-Myers Squibb, Procter & Gamble Pharmaceuticals, Genfit, Millennium, Cerep, GeneLogic, Astex, Amphora, Immunogen, Coley, Mitsubishi Pharmaceutical Corp, Cephalon, Regeneron Pharmaceuticals, Immuno-Design Molecule, ALTANA AG, and Pfizer, Inc.
Sanofi-Aventis is headquartered in Paris, France.
